AREG and prostate carcinoma: Consistent with these observations, we found that BPTES treatment elevated AREG expression in HEK293T cells containing inactive p53 and in p53-deficient PC3 human prostate cancer cells (Fig. 3b and Supplementary Fig. 3a), suggesting that p53 is unlikely to account for the observed AREG regulation by mitochondrial Gln metabolism.